Cancer

  • About the area
  • Groups

The area of ​​cancer research is divided into two differentiated aspects: clinical and laboratory translational research.

Within the clinic, we can currently find four lines of research that have to do with the volume of incidence and prevalence of neoplastic disease, such as: breast cancer, lung cancer, urological tumors and gastrointestinal tumors. Each of them is made up of professionals who are dedicated to the diagnosis, treatment and monitoring of specific neoplasms.

In all lines, there is extensive experience in conducting national and international studies. Many of the members belong to different national and international scientific societies, which allows them to keep in touch with the latest scientific advances. Work is currently underway to increase the specific number of lines of clinical research.

In translational research, the goal has been to detect tumor prognostic factors that allow us to predict the survival of our cancer patients in their different types and stages. The translational research lab has become a benchmark in serum and tissue miRNA detection, and has gained experience in colon cancer.

Currently, collaboration has been started with the Digestive Service, to begin the study of miRNA in gastric cancer, and with the Pneumology Service, to study miRNA in lung cancer. Work is also underway to increase cooperation with all those professionals who are working on some type of cancer.

Area coordination
Enrique Gallardo Diaz

egallardo@tauli.cat

Group A1G1 - Oncological dermatology

Accreditation level: Popup group

Our group for 8 years was experiencing the effects of synchrotron radiation combined with photo-excitable X-ray (RX) drugs. This strategy was used in studies of the effectiveness of new treatments against gliomas. One of the drugs used was cisplatin (cisPt). For more than a year we have moved these studies to new treatments for topical carcinomas.

CisPt is the most widely used and most effective chemotherapy agent against carcinoma in general. Therefore, their topical application may be an effective treatment for invasive local squamous cell carcinoma. Use of this gold-nanoparticle-bound drug (AuNP) guarantees preferential entry into tumor cells, and a concurrence between chemo and subsequent radiotherapy with a low-energy RX apparatus.

These concomitantly administered treatments should allow surgery to be replaced in most annoying and plurimal disease patients, as well as in those cases where surgical access is compromised.

Areas of research

  • Compare the effects of AuNP-bound cisPt and cisPt administered directly in solution with those applied on liposomes, creams or gels.

Composition of the group

  • Manel Sabés Shamaní (Group leader)
  • Mercè Alsina Gibert
  • Marc Corbacho Monné
  • Silvia Gil Duran
  • Mireia Yébenes Marsal

Group A1G2 - Gastrointestinal cancer

Accreditation level: Consolidated group

Areas of research

  • Study of non-coding RNAs (miRNAs and lncRNAs) as potential new biomarkers for colorectal cancer, gastric cancer, and lung cancer.

Composition of the group

  • Carles Pericay Pijaume (Group leader)
  • Natalia Bejarano González
  • Anna Brunet Vega
  • Paula Caresi Aroztegui
  • Francisco Javier Garcia Borobia
  • Neus Garcia Monforte
  • Ismael Macías declares
  • Laura Mora López
  • Anna Pallisera Lloveras
  • Elisa Quílez Tierno
  • Andreu Romaguera Monzonís
  • Neus Ruiz Edo
  • Xavier Serra Aracil
  • Sheila Serra Pla
  • Anna Serracant Barrera

Group A1G3 - Lung cancer

Accreditation level: Popup group

This group focuses on translational and clinical research in the field of non-small cell lung cancer and mesothelioma. For its development the group conducts clinical trials with specific drugs or treatments and carries out projects to investigate in relevant clinical aspects with descriptive studies on evolution in the different pathologies that allow us to implement improvement systems (radiological response patterns, drug toxicities and their evaluation, studies on clinical factors that interfere with therapeutic compliance, etc.).

Areas of research

  • Study of different tumor signaling pathways and gene alterations involved in carcinogenesis and tumor progression of the epithelial-mesenchymal transition process.
  • Mesothelioma: Deepen at the molecular level with mutational study using Next Generation Sequencing techniques and at a pathological level with different immunohistochemical markers of the molecular pathways involved in the progression and carcinogenesis that allow us to design new treatments for orphan disease.
  • Studies in the field of immuno-oncology with studies of patterns of immune response and correlation with clinical factors.

Composition of the group

  • Yolanda García García (Group leader)
  • Marta Andreu Magarolas
  • Lluís Bernà Roqueta
  • Eva Castañer González
  • Lorena Díaz Dam
  • M. Rosa Escoda Giralt
  • Xavier Gallardo Cistaré
  • Antonia Martínez Villegas
  • Rosanna Mirapeix Tailor
  • Carlos Pardo Ruiz
  • Teresa Ribot Berenguer
  • Daniel Ros Monserrate
  • Roser Saumech Perramon
  • Maria Solé Monné
  • Laura Soriano Gutiérrez
  • Laia Vilà Martínez

Group A1G4 - Biomedical research in cancer

Accreditation level: Popup group

Composition of the group

  • Enrique Gallardo Diaz (Group leader)
  • Eva Ballesteros Gómiz
  • Santi Barcons Vilaplana
  • M. Rosa Bella Cueto
  • Carmen Maria Blázques Maña
  • Teresa Bonfill Bee
  • Jordi Branera Pujol
  • Ruben Carrera Salas
  • Irmgard Costa Trachsel
  • Victor by Pedro Ambrosio
  • Carmen Diaz Martín
  • Arturo Dominguez Garcia
  • Joan Carles Ferreres Piñas
  • Dario Garcia Rojo
  • Francisco Javier Guirao Garriga
  • Naim Hannaoui Hadi
  • Antoni Malet Munté
  • Mercedes Moragas Solanes
  • Jesús Muñoz Rodríguez
  • Ruth Orellana Fernández
  • Catalina Padilla Navas
  • Sandra Pérez Aguilera
  • Víctor Pérez Riverola
  • Mario Prenafeta Moreno
  • Jordi Puig Domingo
  • M. Carmen Ramos Guijo
  • Laia Ribot Luna
  • José Antonio Vázquez Luque
  • Pablo Villacé Gallego